<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375895</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2006-002714-35</org_study_id>
    <secondary_id>LOC/06-05</secondary_id>
    <secondary_id>CIC0203/058</secondary_id>
    <nct_id>NCT00375895</nct_id>
  </id_info>
  <brief_title>Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation</brief_title>
  <official_title>Prospective, Open-label, Single Arm Pilot Study Evaluating the Effect on Virological Response of the Switch From Tacrolimus to Cyclosporin Associated With a Peginterferon Alfa-2a / Ribavirin Bitherapy, in Non-responder or With Recurrent VHC+ Disease Liver Transplanted Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may
      lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is
      constant after transplantation and recurrence causes chronic liver disease in 50 to 80% of
      cases. The aim of this study is to assess the efficacy of cyclosporin on C virological
      response. Patients included in the Transpeg 1 study and non-responder or with a recurrent
      disease will be switched from their tacrolimus therapy to cyclosporin, in association with a
      1 year peginterferon alfa-2a / ribavirin bitherapy. Efficacy will be assessed by the
      percentage of patients with a negative qualitative PCR after 19 months of cyclosporin
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may
      lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is
      constant after transplantation. A main factor determining the severity of recurrent hepatitis
      C after transplantation may be immunosuppression. Thus optimization of immunosuppressive
      regimens might be a key aspect to improve the prognosis of chronic hepatitis C in
      transplanted patients. The two most frequently used immunosuppressive drugs are cyclosporin
      and tacrolimus. However, it has been shown that virus replication could be inhibited by
      cyclosporin, through the blockade of cyclophilins, decreasing hepatitis C viral load and
      improving liver function. These effects were not found with tacrolimus.

      The aim of our study is to assess the efficacy on C virological response of the switch from
      tacrolimus to cyclosporin associated with a peginterferon alfa-2a / ribavirin bitherapy, in
      non-responder or with a recurrent VHC+ disease liver transplanted patients.

      Patients will receive a 19 month cyclosporin treatment, associated during 12 months with a
      peginterferon alfa-2a / ribavirin bitherapy. Efficacy will be assessed by the percentage of
      patients with a negative qualitative PCR after 19 months of cyclosporin treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged virological response</measure>
    <time_frame>19 months</time_frame>
    <description>Percentage of patients with a negative qualitative PCR, 19 months after the initiation of cyclosporin treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response 4, 7 and 13 months after the initiation of cyclosporin treatment</measure>
    <time_frame>4, 7 and 13 months</time_frame>
    <description>Percentage of patient with negative or decreased quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response: METAVIR score at 19 months</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response: liver function at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
    <description>Transaminases, gammaGT, alcalin phosphatase, total bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute or chronic graft rejection at 19 months</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death, graft loss and retransplantation at 13 and 19 months</measure>
    <time_frame>13 and 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
    <description>Creatinin clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment discontinuation at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (cancers in particular).</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciclosporin</intervention_name>
    <description>ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.</description>
    <arm_group_label>Ciclosporin</arm_group_label>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 or over,

          -  Who had been included in the Transpeg 1 study,

          -  Non-responders after a three month peginterferon alfa-2a / ribavirin bitherapy or with
             a recurrent disease during the Transpeg 1 maintenance phase, whatever the
             randomization group (ribavirin or placebo),

          -  With a positive qualitative PCR at inclusion,

          -  With a METAVIR histologic score of 1 or more on the last biopsy (done within the 6
             months preceding inclusion),

          -  Treated with tacrolimus for at least 6 months prior to inclusion,

          -  Having given a written informed consent.

        Exclusion Criteria:

          -  Treatment with peginterferon or ribavirin within the 6 months preceding inclusion,

          -  Severe hepatocellular failure or decompensated cirrhosis,

          -  Acute graft rejection within the two months preceding inclusion, or signs of chronic
             rejection on the last biopsy, or retransplantation since inclusion in the Transpeg 1
             study,

          -  Treatment with cyclosporin for more than 6 months during the 24 months preceding
             inclusion,

          -  Treatment with a mTOR inhibitor or with another investigational immunosuppressive
             drug,

          -  Positive serology for HIV or HBV,

          -  Cancer (or history of other malignancy during the last 5 years) except patients
             transplanted for hepatocellular carcinoma and basocellular or excised spinocellular
             carcinoma,

          -  Serious concomitant disease or acute or chronic disorder, other than the current
             transplant, treated with steroids,

          -  Serious cardiac pathology within the last 6 months,

          -  Women with ongoing pregnancy or breast-feeding,

          -  Serious chronic renal failure (creatinine clearance &lt; 30 ml/mn),

          -  Haemoglobin &lt; 10 g/dl, platelets &lt; 50 000/mm3 or neutrophils &lt; 1000 / mm3,

          -  Abnormal TSH values,

          -  Inability to cooperate or to communicate with the investigator,

          -  Contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon Calmus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital Cochin, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'HÃ©patologie - HÃ´pital Jean Minjoz</name>
      <address>
        <city>BesanÃ§on</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'HÃ©patogastroentÃ©rologie - HÃ´pital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'HÃ©patologie et GastroentÃ©rologie - CH Henri Mondor</name>
      <address>
        <city>CrÃ©teil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies de l'Appareil Digestif - CHRU Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie GÃ©nÃ©rale - HÃ´pital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgie GÃ©nÃ©rale - HÃ´pital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'HÃ©pato-gastro-entÃ©rologie - HÃ´pital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgie ViscÃ©rale et Digestive - HÃ´pital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie GÃ©nÃ©rale - HÃ´pital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Foie - HÃ´pital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie GÃ©nÃ©rale et Transplantation Multi-organe - HÃ´pital de la Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'HÃ©pato-gastro-entÃ©rologie - HÃ´pital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre HÃ©pato-Biliaire - HÃ´pital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclosporin</keyword>
  <keyword>Peginterferon</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

